American Thoracic Society International Conference

GDC-0214 Well-Tolerated for Patients with Mild Asthma

August 08, 2020

In a study presented virtually at ATS 2020, investigators find 15 mg of the study drug resulted in a 43% decrease in FeNO.

Tezepelumab Helps Reduce Severe Asthma Exacerbations

August 07, 2020

In a study presented at ATS 2020, investigators test 3 different dosing regimens of tezepelumab in asthma patients with both high and low levels of IL-5 and IL-13.

Expanding the ETHOS Data

June 29, 2020

Where do investigators go next with the 8000-plus COPD patient research?

Topline Sotatercept Results Positive Treating Pulmonary Arterial Hypertension

June 26, 2020

Both dosage groups of the study drug achieved at least a 50-meter increase from baseline to week 24 on the six-minute walk distance test.

Phase 3 Data Points to Treprostinil as a Treatment for Pulmonary Hypertension

June 25, 2020

Treatment with treprostinil of up to 12 breaths per session four-times per data was well-tolerated, with a safety profile consistent with previous studies.

Individualizing COPD Care

June 25, 2020

In an era of triple therapy combinations, what might a tailored approach look like?

Budesonide Plus LAMA/LABA Significantly Reduces Annual COPD Exacerbation

June 24, 2020

New findings from the 8000-plus patient ETHOS trial shows triple inhaler therapy siginificantly betters patient mortality and symptoms over 52 weeks versus dual therapy.

Advancing Biologic Research in Asthma

May 27, 2020

How clinical data for the interleukin-targeting class will begin to dictate more treatement decisions and research progression.

Denise Daley, PhD: Early Asthma Interventions for Infants

May 24, 2020

Asthmatic infants often suffer from other comorbidities throughout their lives.

Continued Three-Year Mepolizumab Sustains Severe Asthma Benefits

May 23, 2020

Blood eosinophil count, exacerbation rate, and time to exacerbation were all bettered among patients who sustained therapy versus those who discontinued.